A RANDOMISED COMPARATIVE STUDY TO COMPARE THE EFFICACY OF TOPICAL TOFACITINIB 2% GEL VS. TOPICAL CORTICOSTEROIDS IN THE TREATMENT OF ATOPIC DERMATITIS
Main Article Content
Keywords
Atopic dermatitis, Tofacitinib, Corticosteroids, Randomized study, JAK inhibitors
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts the quality of life. Topical corticosteroids (TCS) remain the mainstay of treatment, but concerns over side effects necessitate alternative therapies. Tofacitinib, a Janus kinase (JAK) inhibitor, has shown promise in reducing inflammation in immune-mediated conditions.
Objective: To compare the efficacy and safety of topical Tofacitinib 2% gel versus topical corticosteroids in treating atopic dermatitis.
Methods: A randomized, controlled, comparative study was conducted on 100 patients with moderate-to-severe AD. Participants were randomly assigned to receive either Tofacitinib 2% gel or TCS for 8 weeks. Efficacy was assessed using the Eczema Area and Severity Index (EASI) score, pruritus severity score, and patient-reported outcomes.
Results: Patients treated with Tofacitinib showed a significant reduction in EASI scores compared to those receiving TCS (p < 0.05). The pruritus severity score also improved more in the Tofacitinib group. Adverse effects were mild and comparable between groups.
Conclusion: Topical Tofacitinib 2% gel is a promising alternative to TCS in managing moderate-to-severe AD, offering comparable efficacy with a favorable safety profile.
Objective: To compare the efficacy and safety of topical Tofacitinib 2% gel versus topical corticosteroids in treating atopic dermatitis.
Methods: A randomized, controlled, comparative study was conducted on 100 patients with moderate-to-severe AD. Participants were randomly assigned to receive either Tofacitinib 2% gel or TCS for 8 weeks. Efficacy was assessed using the Eczema Area and Severity Index (EASI) score, pruritus severity score, and patient-reported outcomes.
Results: Patients treated with Tofacitinib showed a significant reduction in EASI scores compared to those receiving TCS (p < 0.05). The pruritus severity score also improved more in the Tofacitinib group. Adverse effects were mild and comparable between groups.
Conclusion: Topical Tofacitinib 2% gel is a promising alternative to TCS in managing moderate-to-severe AD, offering comparable efficacy with a favorable safety profile.
References
1. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46.
2. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-94.
3. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
4. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110.
5. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004;50(3):391-404.
6. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.
7. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283-9.
8. Levy LL, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an emerging treatment paradigm. J Drugs Dermatol. 2019;18(11):1049-53.
9. Krueger JG, Ferris LK, Menter A, Wagner F, White A, DiCioccio AT, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137(4):1079-90.
10. Blauvelt A, Silverberg JI, Lynde CW, Guttman-Yassky E, Lacour JP, Spelman L, et al. Phase 3 trials of tofacitinib in atopic dermatitis: efficacy and safety results. J Allergy Clin Immunol. 2019;143(5):1821-30.
11. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015 Mar;72(3):491-3.
12. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-32.
13. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Oda M, Kabashima K, et al. Phase 2 study of baricitinib in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol Sci. 2018;90(3):284-92.
14. Papp KA, Menter A, Raman M, Disch D, Schlichting D, Gaich C, et al. A randomized phase 2 trial of tofacitinib, an oral Janus kinase inhibitor, in the treatment of chronic plaque psoriasis. Br J Dermatol. 2012;167(4):668-77.
15. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis. N Engl J Med. 2016;375(24):2335-48.
16. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. Topical corticosteroids in atopic dermatitis: an EAACI position paper. Allergy. 2018;73(5):983-92.
17. Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Kieras EM, et al. Efficacy and safety of a topical Janus kinase inhibitor for the treatment of atopic dermatitis: results from a randomized phase IIa trial. Br J Dermatol. 2019;180(2):425-33.
18. Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.
2. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-94.
3. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
4. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110.
5. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004;50(3):391-404.
6. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.
7. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283-9.
8. Levy LL, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an emerging treatment paradigm. J Drugs Dermatol. 2019;18(11):1049-53.
9. Krueger JG, Ferris LK, Menter A, Wagner F, White A, DiCioccio AT, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137(4):1079-90.
10. Blauvelt A, Silverberg JI, Lynde CW, Guttman-Yassky E, Lacour JP, Spelman L, et al. Phase 3 trials of tofacitinib in atopic dermatitis: efficacy and safety results. J Allergy Clin Immunol. 2019;143(5):1821-30.
11. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015 Mar;72(3):491-3.
12. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-32.
13. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Oda M, Kabashima K, et al. Phase 2 study of baricitinib in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol Sci. 2018;90(3):284-92.
14. Papp KA, Menter A, Raman M, Disch D, Schlichting D, Gaich C, et al. A randomized phase 2 trial of tofacitinib, an oral Janus kinase inhibitor, in the treatment of chronic plaque psoriasis. Br J Dermatol. 2012;167(4):668-77.
15. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis. N Engl J Med. 2016;375(24):2335-48.
16. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. Topical corticosteroids in atopic dermatitis: an EAACI position paper. Allergy. 2018;73(5):983-92.
17. Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Kieras EM, et al. Efficacy and safety of a topical Janus kinase inhibitor for the treatment of atopic dermatitis: results from a randomized phase IIa trial. Br J Dermatol. 2019;180(2):425-33.
18. Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.
Article Sidebar
Published
Aug 25, 2024
Article Details
How to Cite
Dr. Shraddha Jaywantrao Patil. (2024). A RANDOMISED COMPARATIVE STUDY TO COMPARE THE EFFICACY OF TOPICAL TOFACITINIB 2% GEL VS. TOPICAL CORTICOSTEROIDS IN THE TREATMENT OF ATOPIC DERMATITIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 3501-3504. https://doi.org/10.53555/14cnm984
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biography
Dr. Shraddha Jaywantrao Patil
Assistant Professor, Dept. of Dermatology, Dr. D.Y Patil Medical College, Nerul, Navi Mumbai
How to Cite
Dr. Shraddha Jaywantrao Patil. (2024). A RANDOMISED COMPARATIVE STUDY TO COMPARE THE EFFICACY OF TOPICAL TOFACITINIB 2% GEL VS. TOPICAL CORTICOSTEROIDS IN THE TREATMENT OF ATOPIC DERMATITIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 3501-3504. https://doi.org/10.53555/14cnm984